Clinical Trial Update: Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the efficacy of a combination of polatuzumab vedotin, bendamustine, and rituximab in relapsed/refractory mantle cell lymphoma.…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Bendamustine (Bendamustine)
• Rituximab (rituximab)
• polatuzumab vedotin (polatuzumab vedotin)

Snippet

Sponsor: Medical University of Vienna | Conditions: Mantle-cell Lymphoma | Phase 2 | Status: RECRUITING